Analyst Price Targets — SRRK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 12:55 pm | Allison Bratzel | Piper Sandler | $58.00 | $44.85 | StreetInsider | 'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler |
| March 3, 2026 9:01 pm | Etzer Darout | Barclays | $53.00 | $44.31 | StreetInsider | Scholar Rock (SRRK) PT Raised to $53 at Barclays |
| March 3, 2026 6:54 pm | Srikripa Devarakonda | Truist Financial | $55.00 | $44.31 | StreetInsider | Scholar Rock (SRRK) PT Raised to $55 at Truist Securities |
| January 26, 2026 11:16 am | Andres Maldonado | H.C. Wainwright | $58.00 | $44.29 | TheFly | Scholar Rock price target raised to $58 from $44 at H.C. Wainwright |
| January 7, 2026 6:02 am | Michael Yee | UBS | $60.00 | $41.31 | StreetInsider | UBS Starts Scholar Rock (SRRK) at Buy |
| December 17, 2025 10:58 am | Etzer Darout | Barclays | $52.00 | $44.32 | TheFly | Scholar Rock price target raised to $52 from $45 at Barclays |
| November 14, 2025 5:48 pm | — | BMO Capital | $50.00 | $37.41 | TheFly | Scholar Rock price target raised to $50 from $45 at BMO Capital |
| September 24, 2025 10:39 am | Allison Bratzel | Piper Sandler | $51.00 | $33.75 | TheFly | Scholar Rock price target lowered to $51 from $52 at Piper Sandler |
| September 24, 2025 9:28 am | Etzer Darout | Barclays | $44.00 | $33.39 | TheFly | Scholar Rock price target lowered to $44 from $45 at Barclays |
| September 16, 2025 8:17 pm | — | Barclays | $45.00 | $32.34 | TheFly | Scholar Rock initiated with an Overweight at Barclays |
Latest News for SRRK
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock…
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced it has resubmitted the Biologics License Application…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRRK.
U.S. House Trading
No House trades found for SRRK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.